Replies to post #71086 on Ayala Pharmaceuticals Inc (ADXS)

[mypekeispooped]

I have to question why Ken came out like that about AXAL too as, "Under the terms of the Agreement, Stendhal will pay $10 million toward the expenses of AIM2CERV, a planned global Phase 3 clinical trial in women with high-risk, locally advanced cervical cancer. This payment covers a significant portion of the total planned study costs". I'm hoping a partnership soon as it would same a total waste to let it fall by the wayside. Then again, ADXS-HER2 more than doubled the OS of dogs with osteosarcoma but nobody seemed to want to partner or license it except Aratana.

I think NEO and HOT will be our bread and butter and, I'm guessing, Ken wanted to free up any available cash to push. After PI/II, I believe Amgen will pick up the tab.

[blueyedcatch]

Then we wait for approval